Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Investigating the Efficacy and Activity of Single Agent Erlotinib in Chemotherapy-Naive Androgen Independent Prostate Cancer

NCT00272038 is registered in ClinicalTrials.gov with Oncology Specialists, S.C. as lead sponsor.

NCT NCT00272038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00272038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Investigating the Efficacy and Activity of Single Agent Erlotinib in Chemotherapy-Naive Androgen Independent Prostate Cancer
Lead sponsor
Oncology Specialists, S.C.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
October 31, 2010
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer